Blog

A safety review by the US Food and Drug Administration has shown that medications containing saxagliptin and alogliptin may increase the risk of heart failure in patients who already have heart or kidney disease.

A safety review by the US Food and Drug Administration (FDA) has shown that medications containing saxagliptin and alogliptin may increase the risk of heart failure in patients who already have heart or kidney disease. Popular medications that contain those ingredients include Onglyza® (saxagliptin), Kombiglyze XR (saxagliptin and metformin), Nesina® (alogliptin), Kazano® (alogliptin and metformin), and Oseni® (alogliptin and pioglitazone).

Saxagliptin and alogliptin are dipeptidyl peptidase-4 inhibitor drugs indicated to lower blood sugar in adults with type-2 diabetes when used with diet and exercise. The FDA noticed the increased risk when examining two clinical trials for patients with heart disease. The trials noticed an increased heart failure risk of 25% for patients taking saxagliptin over a placebo and an increased heart failure risk of 18% for patients taking alogliptin over a placebo.

Patients who have a history of heart disease should not take or stop taking any medications without first talking to their doctor. Patients taking these drugs should contact their doctor if they experience any symptom of heart failure, including shortness of breath, difficulty breathing, fatigue, or weight gain with swelling in the feet, ankles, legs, or stomach.

If you or a loved one has been harmed by any dangerous drug, contact The Law Offices of Larry H. Parker today at (800) 333-0000 for a free consultation. We work with a nationally recognized team of pharmaceutical drug trial attorneys with a proven record of success. For more information about some of the different types of harmful drugs please visit our website: The Law Offices of Larry H. Parker.